{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:32:05Z","timestamp":1792290725844,"version":"4.4.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin II (Ang II) type 1 receptor (AT1R) signaling pathway is a key component of the renin-angiotensin-aldosterone system (RAAS) that is involved in the development of hypertension. Chronic Ang II overactivation results in pathological cardiac hypertrophy that progresses into decompensated cardiac dysfunction and impairment. Qingda granule (QDG) is a Traditional Chinese formula that has been used clinically in treating hypertension and its complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to elucidate the role and underlying mechanisms of QDG in preventing Ang II-induced cardiac hypertrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used chronic Ang II infusion via minipumps in mice and administered QDG daily to examine the effects of QDG on preventing hypertension and various parameters of cardiac impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>QDG treatment significantly reduced Ang II-induced elevation in blood pressure. Furthermore, QDG exerted a robust cardioprotective effect on chronic Ang II-induced cardiac hypertrophy and decompensated cardiac dysfunction. QDG also inhibited Ang II-induced adverse NF-\u03baB signaling activation and downstream pro-inflammatory targets, which were prevented via administration with SC75741, a specific NF-\u03baB inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings provide further insight into the robust ability of QDG in preventing Ang II-induced cardiac hypertrophy via preventing NF-\u03baB signaling activation and implicate its use in the clinical treatment of hypertension and cardiac hypertrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1603316","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:00Z","timestamp":1758000960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Qingda granule prevents Ang II-induced cardiac hypertrophy via inhibiting NF-\u03baB signaling pathway"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuhang","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Wo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruokun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"En","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-ni","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cells11213336","article-title":"Angiotensin II-Induced signal transduction mechanisms for cardiac hypertrophy","volume":"11","author":"Bhullar","year":"2022","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","first-page":"113407","DOI":"10.1016\/j.biopha.2022.113407","article-title":"Qingda granule alleviate angiotensin \u2171-induced hypertensive renal injury by suppressing oxidative stress and inflammation through NOX1 and NF-\u03baB pathways","volume":"153","author":"Chen","year":"2022","journal-title":"Biomed. Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111022","DOI":"10.1016\/j.biopha.2020.111022","article-title":"Qingda granule attenuates angiotensin II-induced cardiac hypertrophy and apoptosis and modulates the PI3K\/AKT pathway","volume":"133","author":"Cheng","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1161\/01.Cir.0000164237.58200.5a","article-title":"Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo","volume":"111","author":"Freund","year":"2005","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.3390\/ijms25126661","article-title":"Hypertension and heart failure: from pathophysiology to treatment","volume":"25","author":"Gallo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e12099","DOI":"10.1016\/j.heliyon.2022.e12099","article-title":"Qingda granule prevents obesity-induced hypertension and cardiac dysfunction by inhibiting adverse akt signaling activation","volume":"8","author":"Gao","year":"2022","journal-title":"Heliyon"},{"key":"B7","doi-asserted-by":"publisher","first-page":"112007","DOI":"10.1016\/j.biopha.2021.112007","article-title":"EHP-101 alleviates angiotensin II-induced fibrosis and inflammation in mice","volume":"142","author":"Garc\u00eda-Mart\u00edn","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"153461","DOI":"10.1016\/j.phymed.2021.153461","article-title":"Piperlongumine attenuates angiotensin-II-induced cardiac hypertrophy and fibrosis by inhibiting Akt-FoxO1 signalling","volume":"82","author":"Gu","year":"2021","journal-title":"Phytomedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/pharmrev.120.000236","article-title":"Kidney angiotensin in cardiovascular disease: formation and drug targeting","volume":"74","author":"Lin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11655-024-3807-4","article-title":"Qingda granule attenuates hypertension-induced cardiac damage via regulating renin-angiotensin system pathway","volume":"31","author":"Long","year":"2024","journal-title":"Chin. J. Integr. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115275","DOI":"10.1016\/j.biopha.2023.115275","article-title":"Resveratrol prevents ang II-induced cardiac hypertrophy by inhibition of NF-\u03baB signaling","volume":"165","author":"Ma","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/eurheartj\/ehad842","article-title":"Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice","volume":"45","author":"Ma","year":"2024","journal-title":"Eur. Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/circresaha.116.303697","article-title":"Inflammation, immunity, and hypertensive end-organ damage","volume":"116","author":"Mcmaster","year":"2015","journal-title":"Circ. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10741-019-09855-5","article-title":"The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure","volume":"25","author":"Pugliese","year":"2020","journal-title":"Heart Fail Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"107841","DOI":"10.1016\/j.intimp.2021.107841","article-title":"Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1\/NF-\u03baB pathway","volume":"98","author":"Ren","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1128\/mmbr.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1161\/01.res.86.12.1266","article-title":"Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms","volume":"86","author":"Ruiz-Ortega","year":"2000","journal-title":"Circ. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3389\/fphys.2020.00181","article-title":"Stretch-induced biased signaling in angiotensin II type 1 and apelin receptors for the mediation of cardiac contractility and hypertrophy","volume":"11","author":"Seo","year":"2020","journal-title":"Front. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.7150\/thno.83340","article-title":"OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/cvr\/cvad086","article-title":"Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+\/CaMKII pathway","volume":"119","author":"Wei","year":"2023","journal-title":"Cardiovasc Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ptr.4966","article-title":"Animal studies on medicinal herbs: predictability, dose conversion and potential value","volume":"28","author":"Wojcikowski","year":"2014","journal-title":"Phytother. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"eadu8422","DOI":"10.1126\/sciadv.adu8422","article-title":"Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3","volume":"11","author":"Ye","year":"2025","journal-title":"Sci. Adv."},{"key":"B24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/cvr\/cvp237","article-title":"NF-kappaB activation is required for adaptive cardiac hypertrophy","volume":"84","author":"Zelarayan","year":"2009","journal-title":"Cardiovasc Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1603316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:00Z","timestamp":1758000960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1603316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1603316"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1603316","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1603316"}}